Spots Global Cancer Trial Database for A Study of BKM120 in Adult Japanese Patients With Advanced Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of BKM120 in Adult Japanese Patients With Advanced Solid Tumors
Official Title: A Phase I Study of BKM120, Administered Orally in Adult Japanese Patients With Advanced Solid Tumors
Study ID: NCT01283503
Conditions
Interventions
Study Description
Brief Summary: In this study, BKM120 will be administered to adult patients with advanced solid tumors whose disease has progressed despite standard therapy or for whom no standard therapy exists. The trial will confirm the safety and tolerability and determine the maximum tolerated dose (MTD) of BKM120 in Japanese patients.
Detailed Description:
Keywords
Eligibility
Minimum Age: 20 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Novartis Investigative Site, Nagoya-city, Aichi, Japan
Novartis Investigative Site, Kashiwa, Chiba, Japan
Contact Details
Name: Novartis Pharmaceuticals
Affiliation: Novartis Pharmaceuticals
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
